Immix Biopharma Inc. (NASDAQ: IMMX) has announced study findings demonstrating that its flagship candidate IMX-110 created a 50% response rate in first-line-treatment-resistant cancer- soft tissue sarcoma animal study surpassed the STS standard of care, doxorubicin’s 0% responses rates in a similar animal study.
Study results were analyzed using RECIST 1.1 criteria
In a study financed by the company and carried by a prominent STS cancer treatment facility, the responses were analyzed using RECIST 1.1 criteria used to mice, with progression measured after one cycle of treatment.
CEO ImmixBio Ilya Rachman said, “We strive to test our drug candidates in the most realistic, challenging animal models available. We are thrilled to see that in this first-line-therapy resistant STS model that IMX-110 showed significant activity. We believe this study is a preview of what our SMARxT Platform generating Tissue-Specific Therapeutics can do, a distinct alternative to the traditional ‘single target, single mutation’ development model.”
The United States Food and Drug Administration (“FDA”) has granted IMX-110 orphan drug status for soft tissue sarcoma treatment. In addition, the FDA has already given IMX-110 the classification of rare pediatric disease (“RPD”) for the treatment of rhabdomyosarcoma, a life-threatening juvenile cancer.
ImmixBio has shared IMX-110 clinical data from numerous strongly pretreated patients with several STS subtypes, exhibiting a mean progression-free survival (PFS) of four months with no drug-related serious side events and no dosage interruptions due to toxicity.
STS market expected to hit $6.5 billion by 2030
A soft tissue sarcoma is a form of cancer that starts in the body’s connective, supporting, and surrounding tissues. From an anticipated $2.9 billion in 2019, the worldwide STS market will reach $6.5 billion by 2030. Each year, around 116,000 new instances of STSs are reported worldwide, with 21,500 in the EU and 40,500 in China. As per the American Cancer Society, around 13,000 new cases of STS are expected to be diagnosed in the United States in 2020. Soft tissue cancer affects about 160,000 persons in the United States.
